Research Network Involvement and Addiction Treatment Center Staff: Counselor Attitudes toward Buprenorphine

REFERENCES

• Institute of Medicine. Bridging the Gap between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment. Washington, DC: National Academy Press; 1998.
   Google Scholar
• Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001;61:195–206.
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Kosten T. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend. 2001;63:253–262.
   PubMed Web of Science ®Google Scholar
• Hanson GR, Leshner AI, Tai B. Putting drug abuse research to use in real-life settings. J Subst Abuse Treat. 2002;23:69–70.
   PubMed Web of Science ®Google Scholar
• National Institute on Drug Abuse. National Drug Abuse Treatment Clinical Trials Network. Available at: http://www.nida.nih.gov/CTN/protocol/brochure/2005_ctn_brochure%2010_17_05.pdf. Accessed on August 24, 2006.
   Google Scholar
• Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapies for addiction to alcohol and other drugs. Pharmacol Ther. 2005;108:119–128.
   PubMed Web of Science ®Google Scholar
• Reback CJ, Cohen AJ, Freese TE, Shoptaw S. Making collaboration work: key components of practice/research partnerships. J Drug Issues. 2002;32:837–848.
   Web of Science ®Google Scholar
• Polcin D. Bridging psychosocial research and treatment in community substance abuse treatment programs. Addiction Research and Theory. 2004;12:275–283.
   Web of Science ®Google Scholar
• Arfken CL, Agius E, Dickson MW, Anderson HL, Hegedus AM. Clinicians beliefs and awareness of substance abuse treatments in research- and nonresearch-affiliated programs. J Drug Issues. 2005;35:547–558.
   Web of Science ®Google Scholar
• Ling W, Amass L, Shoptaw S, , et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005;100:1090–1100.
   PubMed Web of Science ®Google Scholar
• Peirce JM, Petry NM, Stitzer ML, , et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment. Arch Gen Psychiatry. 2006;63:201–208.
   PubMed Web of Science ®Google Scholar
• Petry NM, Peirce JM, Stitzer ML, , et al. Effect of prize-based incentives in outcomes in stimulant abusers in outpatient psychosocial treatment programs. Arch Gen Psychiatry. 2005;62:1148–1156.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Ball SA, Nich C, , et al. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend. 2006;81:301–312.
   PubMed Web of Science ®Google Scholar
• Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70:S13–S27.
   PubMed Web of Science ®Google Scholar
• Ling W, Smith D. Buprenorphine: blending practice and research. J Subst Abuse Treat. 2002;23:87–92.
   PubMed Web of Science ®Google Scholar
• Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70:S49–S57.
   PubMed Web of Science ®Google Scholar
• Fudula PJ, Bridge TP, Herbert S, , et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949–958.
   PubMed Web of Science ®Google Scholar
• Lintzeris N, Bell J, Bammer G, Jolley DJ, Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction. 2002:97;1395–1404.
   PubMed Web of Science ®Google Scholar
• Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med. 2000;343:1290–1297.
   PubMed Web of Science ®Google Scholar
• Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60:39–50.
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry. 1994;151:1024–1030.
   Google Scholar
• Amass L, Ling W, Freese TE, , et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004;13:S42–S46.
   PubMed Web of Science ®Google Scholar
• National Drug Abuse Treatment Clinical Trials Network. Buprenorphine/naloxone-facilitated rehabilitation for opioid addicted adolescents/young adults (CTN 0010). Available at: http://www.nida.nih.gov/CTN/protocol/0010.html. Accessed on August 25, 2006.
   Google Scholar
• Klein KJ, Sorra JS. The challenge of innovation implementation. Acad Manage Rev. 1996;21:1055–1080.
   Web of Science ®Google Scholar
• Rogers EM.. The Diffusion of Innovations. 4th ed. New York: Free Press; 1995.
   Google Scholar
• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md.: Substance Abuse and Mental Health Services Administration; 2004.
   Google Scholar
• West JC, Kosten TR, Wilk J, , et al. Challenges to increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13:S8–S16.
   Web of Science ®Google Scholar
• Knudsen HK, Ducharme LJ, Roman PM, Link T. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005;29:95–106.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Wallack SS, Lee S, McCarty D, Swift R. Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat. 2003;24:1–11.
   PubMed Web of Science ®Google Scholar
• Simpson DD. A conceptual framework for transferring research to practice. J Subst Abuse Treat. 2002;22:171–182.
   PubMed Web of Science ®Google Scholar
• Mulligan DH, McCarty D, Potter D, Krakow M. Counselors in public and private alcoholism and drug abuse treatment programs. Alcohol Treat Q. 1989;6:75–89.
   Google Scholar
• Damanpour F. Organizational innovation: a meta-analysis of effects of determinants and moderators. Acad Manage J. 1991;34:555–590.
   Web of Science ®Google Scholar
• Mee-Lee DL, Gartner L, Miller MM, Shulman GD, Wilford BB. Patient Placement Criteria for the Treatment of Substance-Related Disorders. 2nd ed. Chevy Chase, Md.: ASAM; 1996.
   Google Scholar
• Knudsen HK, Johnson JA, Roman PM. Retaining counseling staff at substance abuse treatment centers: effects of management practices. J Subst Abuse Treat. 2003:24;129–135.
   PubMed Web of Science ®Google Scholar
• Forman RF, Bovasso G, Woody G. Staff beliefs about addiction treatment. J Subst Abuse Treat. 2001;21:1–9.
   PubMed Web of Science ®Google Scholar
• Mark T, Kranzler HR, Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003;71:219–228.
   PubMed Web of Science ®Google Scholar
• Kasarabada ND, Hser YI, Parker L, Hall E, Anglin MD, Chang E. A self-administered instrument for assessing therapeutic approaches of drug-treatment counselors. Subst Use Misuse. 2001;36:273–299.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academy Press; 2003.
   Google Scholar